IP Library Patent Application 11239687
Patent Application
App. No. 11/239,687

Treating morning migraines with propranolol

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/239,687
Abstract

This invention relates to a method for preventing and treating morning migraine headaches. Pursuant to this method, a therapeutic amount of β-adrenergic-blocking agent is administered nightly to a person that suffers from migraine attacks such that the blocking agent is first released during morning hours when the person is most susceptible to morning migraine.

Claims (22)

1 . A method for treating a patient that suffers from morning migraines comprising administering a pharmaceutical composition containing a β-adrenergic-blocking agent and one or more pharmaceutically acceptable excipients to the patient in an amount sufficient to provide a therapeutically effective amount of said blocking agent in the morning to prevent or treat morning migraines.

2 . The method of claim 1 , wherein the blocking agent is propranolol, nadolol, timolol, metoprolol, atenolol, labetolol, pindolol, oxprenolol or a salt thereof.

3 . The method of claim 1 , wherein the blocking agent is propranolol or a salt thereof.

4 . The method of claim 3 , wherein the blocking agent is propranolol hydrochloride.

5 . The method of claim 1 , wherein an effective amount of blocking agent is available for a time period between approximately 12:00 midnight to 12:00 noon.

6 . The method of claim 5 , wherein an effective amount of blocking agent is available for a time period between approximately 4:00 AM to 12:00 noon.

7 . The method of claim 6 , wherein an effective amount of blocking agent is available for a time period between approximately 6:00 AM to 11:00 AM.

8 . The method of claim 5 , wherein the time period is at least four hours.

9 . The method of claim 1 , wherein an effective amount of blocking agent is sustained for at least four morning hours.

10 . The method of claim 1 , wherein the blocking agent is administered in a delayed and/or controlled release form.

11 . The method of claim 1 , wherein the composition is administered once daily.

12 . The method of claim 11 , wherein the composition is administered in the evening.

13 . The method of claim 12 , wherein the composition is administered between 8:00 PM and midnight.

14 . The method of claim 13 , wherein the composition is administered at about 10:00 PM.

15 . The method of claim 1 , wherein the composition is administered orally.

16 . The method of claim 15 , wherein the composition is administered in the form of a pill or capsule.

17 . The method of claim 16 , wherein the pill or capsule contains a delayed-release component and a controlled-release component.

18 . The method of claim 17 wherein the delayed-release component is a delayed-release membrane.

19 . The method of claim 17 , wherein the controlled-release component is a controlled-release membrane.

20 . The method of claim 1 , wherein the blocking agent is released continuously for at least four hours for a period between midnight and noon.

21 . The method of claim 20 , wherein the blocking agent is released continuously for at least four hours for a period between 4:00 AM and noon.

22 . The method of claim 21 , wherein the blocking agent is released continuously for at least four hours for a period between 6:00 AM and 11:00 AM.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jul 26, 2010
From: GOLDMAN SACHS CREDIT PARTNERS L.P., AS COLLATERAL AGENT
To: RELIANT PHARMACEUTICALS, INC.
Reel/Frame 024741/0060 →
SECURITY AGREEMENT Recorded May 9, 2007
From: RELIANT PHARMACEUTICALS, INC.
To: GOLDMAN SACHS CREDIT PARTNERS, L.P., AS COLLATERAL AGENT
Reel/Frame 019265/0086 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2006
From: ROTENBERG, KEITH S.; BOBOTAS, GEORGE
To: RELIANT PHARMACEUTICALS, INC.
Reel/Frame 017485/0735 →